WHO Global ARVs and Diagnostic Use Survey in 2015 in Low & Middle-Income Countries

ARV use situation by end of 2014
Preliminary Results

Dr Vincent Habiyambere
AIDS Medicines and Diagnostic Service (AMDS)
Strategic Information and Planning Unit
WHO HIV Department
March 2016
WHO Global ARV Use Survey in 2015

- 87 LMIC countries: 39 AFRO; 17 PAHO; 9 EMRO; 7 EURO; 5 SEARO; 10 WPRO countries
- 12.4 millions patients (91%) on ART out of the total of 13.6 M in LMIC (14.9M) by end 2014.
- 94.6% adults vs 5.4% children
- 94.1% on 1st line; 5.3 on 2nd line; 0.6 on 3rd line.
- 11.7 M adults: 94.1% on 1st line; 5.3% for 2nd line and 0.6% for 3rd line.
- 0.7 M children: 94.5% on 1st line; 5.3% on 2nd line and 0.2% on 3rd line.
Major first-line regimens used in adults in LMI countries: 94.1% n=11,044,481

- 29% AZT use, 1% d4T use, 69% TDF
- 35% NVP and 65% EFV use
- 77% 3TC use and 23% FTC use.
- 96% of patients in 1st line use 5 regimens
Evolution of d4T, AZT and TDF use in adult 1st line therapy* (2009-2015)

*18 countries which have been followed since 2009 and have complete report in all years: Botswana, Burkina Faso, Burundi, Cambodia, Cameroun, China, Ethiopia, Ghana, Iran, Kenya, Malawi, Namibia, Nigeria, DRC, Uganda, Ukraine, Zambia, and Zimbabwe
Evolution of 1 and 2nd line ART therapy in adults* (2009-2015)

*18 countries which have been followed since 2009 and have complete report in all years: Botswana, Burkina Faso, Burundi, Cambodia, Cameroun, China, Ethiopia, Ghana, Iran, Kenya, Malawi, Namibia, Nigeria, DRC, Uganda, Ukraine, Zambia, and Zimbabwe.
Second-line regimens used in adults/ado in LMI countries by end of 2014: 5.3% of adults on ART
n=462,301

- 26% AZT use,
- 68% TDF, 6% ABC
- 83% LPV, 17% ATV
- 88% 3TC, 11% FTC & 1% ddl.
- More fragmentation for less number of people.
Main 3rd-line regimens used in adults & adolescents in LMI countries by end of 2014: 0.6 % of adults/ado on ART (n=14,611)
Evolution of PIs use in 2nd line ARV regimens used for adults & adolescents* (2009-2015)

*18 countries which have been followed since 2008 and have complete report in all years: Botswana, Burkina Faso, Burundi, Cambodia, Cameroun, China, Ethiopia, Ghana, Iran, Kenya, Malawi, Namibia, Nigeria, DRC, Uganda, Ukraine, Zambia, and Zimbabwe.
PEDIATRIC ART
Main First-line regimens used in children in LMI countries by end of 2014
n=626,091

- 56% AZT use,
- 6% d4T, and
- 35% ABC, 2% TDF

- 18% LPV/r, 56% NVP & 25% EFV

- 99.6% 3TC, 0.4% FTC
Evolution of AZT, d4T, ABC and TDF use in 1\textsuperscript{st} line pediatric therapy* (2009-2015)
Evolution of AZT, d4T, ABC and TDF use in 1st line pediatric therapy* (2009-2015)
Main second-line regimens used in children in LMI countries by end of 2014: 5.3% of children on ART (n=33,119)

- 3% d4T use,
- 32% ABC,
- 38% AZT,
- 27% TDF
- 91% LPV/r;
- 3.5% ATV;
- 5% IDV & 0.2% DRV
Main 3rd-line regimens used in children in LMI countries by end of 2014: 0.2% of children on ART (n=1,107)

- 45% TDF; 4% AZT; 3% ABC
- 23% EFV; 17% LPV; 6% NVP; 2% DRV; 1% RAL
THANK YOU